Volume 2 Issue 1
Jan.  2011
Turn off MathJax
Article Contents
Wei-gang YAN, Han-zhong LI, Yi ZHOU, Jian CHEN, Hong-jun LI, Fu-quan ZHANG. Outcomes of Prostate Cancer Patients after Brachytherapy[J]. Medical Journal of Peking Union Medical College Hospital, 2011, 2(1): 24-27. doi: 10.3969/j.issn.1674-9081.2011.01.005
Citation: Wei-gang YAN, Han-zhong LI, Yi ZHOU, Jian CHEN, Hong-jun LI, Fu-quan ZHANG. Outcomes of Prostate Cancer Patients after Brachytherapy[J]. Medical Journal of Peking Union Medical College Hospital, 2011, 2(1): 24-27. doi: 10.3969/j.issn.1674-9081.2011.01.005

Outcomes of Prostate Cancer Patients after Brachytherapy

doi: 10.3969/j.issn.1674-9081.2011.01.005
More Information
  • Corresponding author: LI Han-zhong   Tel:010-65296035, E-mail:lihanzhong@medmail.com.cn
  • Received Date: 2010-11-05
  • Publish Date: 2011-01-30
  •   Objective  To evaluate the effectiveness and complications of prostate brachytherapy.  Methods  We enrolled 27 prostate cancer patients aged 63 to 81 years(mean:75 years)in our study, with 16 at the clinical stage of T1cN0M0, 11 at T2aN0M0, and 14 with Gleason score of 5, 13 with Gleason score of 6. Their serum prostate specific antigen(PSA)levels ranged 2.8-18.6 μg/L(mean:8.5 μg/L). All of them underwent 125I seed implantation with the D90 of 140-155 Gy and had the serum PSA levels routinely determined after the procedure.Effectiveness and complications were also observed. None of the 27 patients were treated with hormone therapy.  Results  Follow-up ranged from 12 to 74 months(mean:44 months). The median nadir PSA was 0.18 μg/L, with only 2 above 1.0 μg/L. One year after brachytherapy, the median level of serum PSA was 0.71 μg/L(mean:0.92 μg/L), and 17 with the level under 1.0 μg/L. Two patients(7%)experienced biochemical failure at the 30 month and 48 month after the procedure. Two patients(7%)developed acute urinary retention, which was released after catheterization for 1 week. Low urinary tract symptoms were observed in 24 patients, which were improved 6-12 months later. No prostate-rectal fistula was observed. Seventeen patients erected efficiently before brachytherapy, while 10 preserved erection in different levels after brachytherapy. The incidence of erectile dysfunction was 41%(7/17).  Conclusion  Prostate brachytherapy is an effective treatment for low- and intermediate-risk patients with acceptable complications. Most patients can preserve sexual function after this procedure.
  • loading
  • [1] Nag S.Brachytherapy for prostate cancer:summary of American Brachytherapy Society recommendations[J].Semin Urol Oncol, 2000, 18:133-136. http://cn.bing.com/academic/profile?id=22e1518b4f4cb88da1d92804498877bf&encoded=0&v=paper_preview&mkt=zh-cn
    [2] Roach Ⅲ, Hanks G, Thames H, et al.Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer:recommendations of the RTOG-ASTRO phoenix consensus conference[J].IntJ RadiatOncol Biol Phys, 2006, 65:965-974. doi:  10.1016/j.ijrobp.2006.04.029
    [3] Taira AV, Merrick GS, Butler WM, et al.Long-term out-come forclinically localized prostate cancertreated with permanent interstitial brachytherapy[J/OL].Int J Radiat Oncol Biol Phys (2010-06-02).http://www.sciencedirect.com/science/journal/03603016.
    [4] Mayadev J, Merrick GS, Reed JR, et al.Permanent prostate brachytherapy in prostate glands < 20 cm[J].Int J Radiat Oncol Biol Phys, 2010, 76:1450-1455. doi:  10.1016/j.ijrobp.2009.04.014
    [5] Mitchell DM, Swindell R, Elliott T, et al.Analysis of prostate-specitic antigen bounce after I125 permanent seed implant for localised prostate cancer[J].Radiother Oncol, 2008, 88:102-107. doi:  10.1016/j.radonc.2008.04.004
    [6] Ellis WJ.Prostate brachytherapy[J].Cancer Met Rev, 2002, 21:125-129. doi:  10.1023/A:1020871707029
    [7] South Cape Urology.Why Brachytherapy[R/OL].http://www.southcapeurology.co.za/brachytherapy/why.html.
    [8] Stamey TA, Caldwell M, McNeal JE, et al.The prostatespecific antigen era in the United States is over for prostate cancer:What happened in the last 20 years[J].J Urol, 2004, 172:1297-1301. doi:  10.1097/01.ju.0000139993.51181.5d
    [9] Zeitman AL, Coen JJ, Shipley WU, et al.Radical radiation therapy in the management of prostatic adenocarcinoma:the initial prostate specific antigen value as a predictor of treatment outcome[J].J Urol, 1994, 151:640-645. doi:  10.1016/S0022-5347(17)35036-X
    [10] Merrick GS, Bulter WM, Lief JH, et al.Five-year biochemical outcome after prostate brachytherapy for hormonena ve men < or=62 years of age[J].Int J Radiat Oncol Biol Phys, 2001, 50:1253-1257. doi:  10.1016/S0360-3016(01)01539-5
    [11] Pinkawa M, Piroth MD, Holy R, etal.Prostate-specific antigen kinetics following external-beam radiotherapy and temporary (Ir-192) or permanent (I-125) brachytherapy for prostate cancer[J].Radiother Oncol, 2010, 96:25-29. doi:  10.1016/j.radonc.2010.02.010
    [12] Iannuzzi CM, Stock RG, Stone NN.PSA kinetics following I-125 radioactive seed implantation in the treatment of T1-T2 prostate cancer[J].Radiat Oncol Investig, 1999, 7:30-35. doi:  10.1002/(SICI)1520-6823(1999)7:1<30::AID-ROI4>3.0.CO;2-8
    [13] Ray ME, Thanes HD, Levy LB, etal.PSAnadir predicts biochemical and distatantfailures afterexternal beamradiotherapy for prostate cancer:a mult-institutional analysis[J].Int J Radiat Oncol Biol Phys, 2006, 64:1140-1150. doi:  10.1016/j.ijrobp.2005.07.006
    [14] Stone NN, Stock RG.Complications following permanent prostate brachytherapy[J].Euro Urol, 2002, 41:427-433. doi:  10.1016/S0302-2838(02)00019-2
  • 加载中


    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (149) PDF downloads(7) Cited by()
    Proportional views


    DownLoad:  Full-Size Img  PowerPoint